FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

15 results

cabenuva
(cabotegravir and rilpivirine)
ViiV Healthcare Company
Usage: CABENUVA is indicated for the treatment of HIV-1 in adults and adolescents (12 years and older, 35 kg+) as a complete regimen to replace current antiretroviral therapy in those who are virologically suppressed, with no history of treatment failure or known resistance to its components.
complera
(emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate)
Gilead Sciences, Inc.
Usage: COMPLERA® is indicated for treating HIV-1 in adults and children (≥35 kg) as initial therapy for those with no treatment history and HIV-1 RNA ≤100,000 copies/mL, or to replace a stable regimen in virologically suppressed patients. Limitations include risk of virologic failure in those with higher baseline HIV-1 RNA.
delstrigo
(doravirine, lamivudine, and tenofovir disoproxil fumarate)
Merck Sharp & Dohme LLC
Usage: DELSTRIGO® is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg, either as a complete regimen for those with no prior antiretroviral treatment or to replace the current regimen in patients who are virologically suppressed with no history of treatment failure.
dovato
(dolutegravir sodium and lamivudine)
ViiV Healthcare Company
Usage: DOVATO is indicated for the treatment of HIV-1 infection in adults and adolescents (aged 12 and older, weighing at least 25 kg) either as a complete regimen for those with no prior treatment history or to replace the current regimen in virologically suppressed patients without resistance concerns.
evotaz
(atazanavir and cobicistat)
E.R. Squibb & Sons, L.L.C.
Usage: EVOTAZ® is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents for adults and pediatric patients weighing at least 35 kg. Its use in treatment-experienced patients should be guided by baseline protease inhibitor resistance.
fuzeon
(Enfuvirtide)
Genentech, Inc.
Usage: FUZEON® is indicated for the treatment of HIV-1 infection in treatment-experienced patients who show evidence of ongoing HIV-1 replication despite receiving antiretroviral therapy, in combination with other antiretroviral agents.
lamivudine
(lamivudine oral)
Chartwell RX, LLC
Usage: Lamivudine oral solution is indicated in combination with other antiretroviral agents for treating HIV-1 infection. It is not intended for use in hepatitis B virus (HBV) treatment.
odefsey
(emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide)
Gilead Sciences, Inc.
Usage: ODEFSEY is indicated for the treatment of HIV-1 infection in patients weighing at least 25 kg, either as initial therapy for those with no prior treatment history and HIV-1 RNA ≤ 100,000 copies/mL, or to replace a stable regimen in virologically suppressed patients.
pifeltro
(doravirine)
Merck Sharp & Dohme LLC
Usage: PIFELTRO® is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥35 kg) in combination with other antiretroviral agents, either for those with no prior treatment history or to replace a stable regimen in virologically-suppressed patients without treatment failure history.
prezcobix
(DARUNAVIR ETHANOLATE and COBICISTAT)
Janssen Products LP
Usage: PREZCOBIX is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents for both treatment-naïve and treatment-experienced adults and pediatric patients (weighing at least 40 kg) without specific darunavir resistance mutations.

Medications for Human Immunodeficiency Virus I Infection

cabenuva

complera

delstrigo

dovato

evotaz

fuzeon

lamivudine

odefsey

pifeltro

prezcobix